Summary
- Current Price
- As of today, RARE price is $20.52, down -12.68% on
- Current Price All-Time High
- RARE price is currently -88.58% below its historical high of $179.65 set on
- Market Cap
- RARE current market cap is $2B, down -50.82% year-over-year
- PE Ratio
- RARE PE ratio is unknown
- Revenue
- RARE current annual revenue is $560.23M, up +29.01% year-over-year
- Next Earnings
- As of today, the next earnings release for RARE has not been scheduled
Profile
| Metric | Value |
|---|---|
| Full Name | Ultragenyx Pharmaceutical Inc. |
| Ticker | NASDAQ: RARE |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | ultragenyx.com |
| Employees | 1,294 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $20.52 | |
| Price, 1D Change | -12.68% | |
| $2B | ||
| - | ||
| - | ||
| 0.95 | ||
| $560M | ||
| Revenue, 1Y Change | +29.01% | |
| -$6.29 | ||
| EPS, 1Y Change | +23.79% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | N/A | |
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| -$6.29 | ||
| EPS Estimate | N/A | -$5.64 |
| EPS Est. Change | N/A | +10.34% |
| $560.23M | ||
| Revenue Estimate | N/A | $668.09M |
| Revenue Est. Change | N/A | +19.25% |
| Current Price | $20.52 | |
| Price Target | - | $56.00 |
| Price Tgt. Change | - | +172.90% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$6.17 | -$6.29 | -1.97% | |
| -$5.64 | N/A | +10.34% | |
| -$3.00 | N/A | +52.34% | |
| -$1.23 | N/A | +80.39% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $554.66M | $560.23M | +1.00% | |
| $668.09M | N/A | +19.25% | |
| $778.14M | N/A | +38.90% | |
| $1.08B | N/A | +92.00% |
🔒 Log In To Unlock Full Data
Performance
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $20.52 | |
| $31.34 | ||
| SMA 200 vs Price | +52.72% | |
| $27.50 | ||
| SMA 50 vs Price | +34.01% | |
| 0.95 | ||
| $1.47 | ||
| 30.17 | ||
| 73.40% | ||
| 70.32% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| $560.23M | ||
| -$6.29 | ||
| $453.46M | ||
| 80.94% | ||
| -$535.97M | ||
| -95.67% | ||
| -$569.18M | ||
| -101.60% | ||
| -$504.55M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| 3.56 | ||
| 2.37 | ||
| 2.03 | ||
| - | ||
| 3 | ||
| -3.08 |
Valuations
| Metric | Date | Value |
|---|---|---|
| - | ||
| 3.14 | ||
| 216.15 | ||
| -4.73 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| $255.30M | ||
| $173.73M | ||
| $1.50B | ||
| $745.03M | ||
| $1.24B | ||
| $344.15M | ||
| $910.01M | ||
| $60.14M | ||
| $38.76M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $1.10B | ||
| $1.02B | ||
| $106.77M | ||
| $321.61M | ||
| $35.54M | ||
| $0.00 | ||
| $1.60M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$414.19M | ||
| -$17.77M | ||
| $399.24M | ||
| $19.99M | ||
| -$434.18M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Cantor Fitzgerald | → | |
| TD Cowen | → | |
| Cantor Fitzgerald | → | |
| RBC Capital | → | |
| Cantor Fitzgerald | → | |
| Cantor Fitzgerald | → | |
| Barclays | → | |
| Wells Fargo | → | |
| Wedbush | → | |
| Goldman Sachs | → |
Analyst sentiment
Institutional ownership
Screeners with RARE
FAQ
What is the ticker symbol for Ultragenyx Pharmaceutical Inc.?
The ticker symbol for Ultragenyx Pharmaceutical Inc. is NASDAQ:RARE
Does Ultragenyx Pharmaceutical Inc. pay dividends?
No, Ultragenyx Pharmaceutical Inc. does not pay dividends
What sector is Ultragenyx Pharmaceutical Inc. in?
Ultragenyx Pharmaceutical Inc. is in the Healthcare sector
What industry is Ultragenyx Pharmaceutical Inc. in?
Ultragenyx Pharmaceutical Inc. is in the Biotechnology industry
What country is Ultragenyx Pharmaceutical Inc. based in?
Ultragenyx Pharmaceutical Inc. is headquartered in United States
When did Ultragenyx Pharmaceutical Inc. go public?
Ultragenyx Pharmaceutical Inc. initial public offering (IPO) was on January 31, 2014
Is Ultragenyx Pharmaceutical Inc. in the S&P 500?
No, Ultragenyx Pharmaceutical Inc. is not included in the S&P 500 index
Is Ultragenyx Pharmaceutical Inc. in the NASDAQ 100?
No, Ultragenyx Pharmaceutical Inc. is not included in the NASDAQ 100 index
Is Ultragenyx Pharmaceutical Inc. in the Dow Jones?
No, Ultragenyx Pharmaceutical Inc. is not included in the Dow Jones index
When was Ultragenyx Pharmaceutical Inc. last earnings report?
Ultragenyx Pharmaceutical Inc.'s most recent earnings report was on February 12, 2026
When does Ultragenyx Pharmaceutical Inc. report earnings?
The date for Ultragenyx Pharmaceutical Inc.'s next earnings report has not been announced yet
Data Sources & References
- RARE Official Website www.ultragenyx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1515673/000119312525265126/0001193125-25-265126-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1515673/000095017025023312/0000950170-25-023312-index.htm
- RARE Profile on Yahoo Finance finance.yahoo.com/quote/RARE
- RARE Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rare